Several methodological issues in the draft evidence report for oral semaglutide are likely biasing the results toward an overly restrictive cost-effectiveness result. These issues include:
- Not adequately accounting for the additional patient benefits that a once-daily oral formulation provides
- Not adequately accounting for the co-morbidities associated with Type 2 diabetes
- Underestimating the full costs Type 2 diabetes impose on patients and their caregivers
- Not adequately accounting for the well-documented heterogeneity across Type 2 diabetes patients.
